Biometry
Biometry is a healthcare technology company focused on asthma management through biomarker data and predictive analytics.
Profile
Predicts asthma attacks using breath biomarkers and environmental data to guide patient self-management.
Biometry is a healthcare technology company focused on asthma management through biomarker data and predictive analytics. Founded to address the gap in proactive asthma care, the company developed a patented sensor that measures fractional exhaled nitric oxide (FeNO) in breath to assess airway inflammation. This biological data, combined with environmental and clinical risk factors, powers their predictive engine to forecast asthma attacks before symptoms occur.
Their system includes a home-use device, mobile app for monitoring, and personalized risk models that trigger alerts and deliver CDC-recognized education programs. While not yet FDA-cleared as of 2026, the technology targets the 25 million asthma sufferers in the U.S., particularly those with uncontrolled symptoms. The company operates in a competitive space dominated by traditional inhaler manufacturers and emerging digital health platforms.
Recent industry shifts, such as Amazon's discontinuation of its Amazon One biometric payment system, highlight both the potential and challenges in biometric healthcare applications. Biometry's approach aligns with growing demand for preventive care tools but faces hurdles in clinical validation and reimbursement pathways.
Who buys this
- Patients with moderate-to-severe asthma
- Pulmonology clinics and allergists
- Health insurers managing high-risk populations
- Employer wellness programs
- Clinical research organizations studying respiratory diseases
Strengths and what to watch
Strengths
- Patented FeNO sensor technology for at-home airway inflammation measurement
- CDC-recognized education programs integrated into the platform
- Combines biological, environmental, and clinical data for personalized risk modeling
Watch for
- Lack of FDA clearance as of 2026 limits commercial deployment
- Dependence on patient adherence to daily breath measurements
- Competition from pharmaceutical companies integrating sensors into inhalers
Key Information
- Founded
- 2013
- Headquarters
- United States Massachusetts. Biometry
Frequently Asked Questions
What is Biometry and what do they do?
Biometry is a healthcare technology company focused on asthma management. They use breath biomarkers and environmental data to predict asthma attacks, helping patients manage their condition proactively. Their system includes a home-use device, mobile app, and personalized risk models.
How does Biometry predict asthma attacks?
Biometry predicts asthma attacks by measuring fractional exhaled nitric oxide (FeNO) in breath using a patented sensor. This data, combined with environmental and clinical risk factors, powers their predictive engine to forecast asthma attacks before symptoms occur.
What technology does Biometry use for asthma management?
Biometry uses a patented FeNO sensor to measure airway inflammation in breath. This sensor integrates with a mobile app and predictive analytics platform, combining biological, environmental, and clinical data to provide personalized asthma management and CDC-recognized education programs.
Who uses Biometry's asthma management system?
Biometry's system targets patients with moderate-to-severe asthma, pulmonology clinics, health insurers managing high-risk populations, employer wellness programs, and clinical research organizations studying respiratory diseases. It aims to improve proactive asthma care for these diverse user groups.
Is Biometry FDA-cleared for asthma management?
As of 2026, Biometry's asthma management technology is not yet FDA-cleared. This limits its commercial deployment, though it continues to target the 25 million asthma sufferers in the U.S., particularly those with uncontrolled symptoms.
What are the challenges for Biometry in the asthma market?
Biometry faces challenges including lack of FDA clearance, dependence on patient adherence to daily breath measurements, and competition from pharmaceutical companies integrating sensors into inhalers. Despite these hurdles, their technology aligns with growing demand for preventive asthma care tools.
Sources
- www.mybiometry.com — Company's product offerings and technology description
- www.reuters.com — Industry context regarding biometric technology challenges
- techcrunch.com — Relevance of biometric data security concerns
- techcrunch.com — General tech industry trends affecting healthcare startups